CURE ETF

After recently taking profit in the CURE ETF, we again add the name back onto our watchlist and identify the range where we expect buying support to rebuild.

Buy $58.50 target.

Separate to the above opportunity, we see upside in the large-cap biotech stocks in the US. In particular, we like Abbvie, Biogen, Gilead, Johnson & Johnson, Merk, and Pfizer.

If you’d like to discuss setting up a US broking account with Investor Signals, please call me on 1300 614 002.

Resmed – Strong Earnings

ResMed is under Algo Engine buy conditions and is a current holding in our ASX model portfolio.

Resmed reported better than expected 1Q21 earnings with group revenue up 10% and NPAT up 37% on the same time last year.

At 35x PE Resmed remains expensive and will need to maintain double-digit earnings growth to sustain the current valuation.

Buy on future share price weakness.